Poster #436

Are Healthcare Professionals Appropriately Screening for Hepatitis Delta Virus in Patients With Chronic Hepatitis B? Results From an Interactive Decision Support App

Sarah L. Anderson, PharmD, BCACP, FASHP, FCCP;
Jacqueline A. Meredith, PharmD, BCIDP;
Zachary Schwartz, MSc, ELS; Maria Buti, MD.

Background

- Patient variables informing HBV and HDV management are complex and interconnected
- HCPs must consider HBeAg status, HBV DNA level, fibrosis, and renal or bone alterations when making treatment decisions
- A point-of-care app, *Hep B Consult*, was developed for HCPs to receive **patient-tailored guideline recommendations** based on HCP-entered patient case data

Try the *Hep B Consult* app

Aim

- Use *Hep B Consult* app results to examine whether HCPs following EASL guidance were appropriately working up patients for HBV and HDV

Cases Entered

- **419 cases** were entered by **206 HCP learners** into the *Hep B Consult* app between March 3, 2023, and December 8, 2023, after choosing EASL as their preferred guidance


ALT, alanine aminotransferase; EASL, European Association for the Study of the Liver; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCP, healthcare professional; HDV, hepatitis delta virus.

Supported by an educational grant from Gilead Sciences, Inc.


HCP Learner Demographics

n = 212 cases entered by HCPs who identified their country

HCP Type



Location



Top 3 European Countries

United Kingdom
Italy
Portugal

Results of HCPs' Patient Workup

Laboratory Data

	n/N
HBeAg	419/419
HBV DNA	419/419
ALT	419/419
Fibrosis assessment	419/419
Bone disease assessment	419/419
Renal assessment	419/419

Key Results

HDV assessment	313/419

Key Results

HDV antibodies were **not** screened in 25.3% (106/419) of cases

Of the 78 cases where the patient was HDV antibody positive, 8.9% did **not** have follow-up screening of HDV RNA

Conclusion

- HCPs who used the *Hep B Consult* app to enter a patient case demonstrated comprehensive patient workup ***with the exception of HDV status***
- This behavior is not aligned with EASL HDV guidelines, which recommend screening all people who are HBsAg positive for HDV at least once
- HCPs need education on the importance of screening all people with HBV for HDV

More Information

See our separate educational program to address these knowledge gaps

Author Disclosures

Sarah Anderson, PharmD, BCACP, FASHP, FCCP, has no relevant financial relationships to disclose.

Jacqueline A. Meredith, PharmD, BCIDP, has no relevant financial relationships to disclose.

Zachary Schwartz, MSc, ELS, has no relevant financial relationships to disclose.

Maria Buti, MD: consultant/advisor/speaker: AbbVie, Gilead, GlaxoSmithKline, Janssen.

Find this poster online

powered by cea